In the last trading session, 1.55 million Prime Medicine Inc (NASDAQ:PRME) shares changed hands as the company’s beta touched 1.83. With the company’s per share price at $2.59 changed hands at -$0.06 or -2.26% during last session, the market valuation stood at $339.71M. PRME’s last price was a discount, traded about -277.22% off its 52-week high of $9.77. The share price had its 52-week low at $2.56, which suggests the last value was 1.16% up since then. When we look at Prime Medicine Inc’s average trading volume, we note the 10-day average is 0.82 million shares, with the 3-month average coming to 1.09 million.
Analysts gave the Prime Medicine Inc (PRME) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.20. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PRME as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Prime Medicine Inc’s EPS for the current quarter is expected to be -0.31.
Prime Medicine Inc (NASDAQ:PRME) trade information
Instantly PRME was in red as seen at the end of in last trading. With action -8.48%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -11.30%, with the 5-day performance at -8.48% in the red. However, in the 30-day time frame, Prime Medicine Inc (NASDAQ:PRME) is -13.38% down. Looking at the short shares, we see there were 17.21 million shares sold at short interest cover period of 15.18 days.
The consensus price target for the stock as assigned by Wall Street analysts is 17, meaning bulls need an upside of 84.76% from its current market value. According to analyst projections, PRME’s forecast low is 12 with 23 as the target high. To hit the forecast high, the stock’s price needs a -788.03% plunge from its current level, while the stock would need to soar -363.32% for it to hit the projected low.
Prime Medicine Inc (PRME) estimates and forecasts
Data shows that the Prime Medicine Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -47.14% over the past 6 months, a 17.24% in annual growth rate that is considerably higher than the industry average of 15.90%.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 5.81M. 6 analysts are of the opinion that Prime Medicine Inc’s revenue for the current quarter will be 3.79M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 541.57%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -193.88%. The 2025 estimates are for Prime Medicine Inc earnings to increase by 26.60%, but the outlook for the next 5-year period is at 20.17% per year.
PRME Dividends
Prime Medicine Inc is expected to release its next quarterly earnings report in March.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 23.91% of Prime Medicine Inc shares while 62.40% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 82.00%.
Among Mutual Funds, the top two as of Nov 30, 2024 were ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF. With 2.63 shares estimated at $6.81 million under it, the former controlled 2.00% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Innovation ETF held about 1.80% of the shares, roughly 2.36 shares worth around $6.12 million.
